From the 8-K: 9.9.13: "The acquisition includes the PolyMedix pipeline of nine compounds as well as the substantial equipment assets at PolyMedix’s 25,000-square-foot headquarters and laboratory."
Less than two years ago, PolyMedix had 28 employees, a market capitalization of $227.4 million and was rated as “outperform” by a well-known investment banking firm.
Otherwise CTIX IPIX has 8 Compounds - so 8 + 9 = 17
Kevetrin Cancer KM 133 Psoriasis KM 391 Autism KM 277 Arthritis KM 278 Arthritis/Asthma KM 362 MS/ALS/Parkinsons KM-3174 Cancer KM-732 Hypertensive emergency
Here are RIGHTS associated with:
Payments Related to Assignment of Compounds
The Company has been assigned all rights, title, and interest to the following eight pharmaceutical compounds: Kevetrin, KM 277, KM 278, KM 362, KM 3174, KM 732, and KM-391. The Company agreed to pay the assignors 5% of net sales of the compounds in countries where composition of matter patents have been issued and 3% of net sales in other countries. Kevetrin, KM 277, KM 278 and KM 362 were acquired by the Company from Dr. Krishna Menon, a Director, the Company’s President of Research and Chief Scientific Officer, and a principal shareholder. With regard only to Kevetrin, the allocation of the 5% of net sales would be as follows: 2% to Dr. Menon, 2% to an unaffiliated third party, and 1% to Leo Ehrlich, our CEO. With respect to KM 732, the Company has agreed to pay an individual a fixed payment if the compound is approved for sale in the U.S. The Company owns all rights to Prurisol.
News 
Market Data 
Discover 
